Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Kali Therapeutics

HQ: San Mateo, CA source · kalitherapeutics.com ↗

Clinical Phase 1

Keywords: immunology inflammatory diseases Rheumatoid Arthritis KT502 KT501

Location: San Mateo, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Jul 13, 2026 Trial start Phase 1: A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA) source ↗
Mar 6, 2026 Trial start Phase 1: A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). source ↗

Upcoming milestones

2027-02 (ESTIMATED) · Phase 1 · A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA). · NCT07234773
2027-12 (ESTIMATED) · Phase 1 · A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA) · NCT07564154

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07564154	A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)	Phase 1	Recruiting	Jul 13, 2026	2027-12 (estimated)
NCT07234773	A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).	Phase 1	Recruiting	Mar 6, 2026	2027-02 (estimated)